|
|
Vaccine Detail
|
P30-linked EphA2/CMV pp65/Survivin Peptide Vaccine P30-EPS |
| Vaccine Information |
- Vaccine Name: P30-linked EphA2/CMV pp65/Survivin Peptide Vaccine P30-EPS
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007717
- Type: Subunit vaccine
- Status: Clinical trial
- Host Species for Licensed Use: None
- Antigen: P30-linked EphA2, CMV pp65, and survivin peptides (NCT05283109; NCIT_C187131)
- Immunization Route: Other
- Description: This is a peptide vaccine comprised of three immunogenic tetanus toxoid epitope P30-linked tumor-associated antigen (TAA) peptides, P30-linked Ephrin receptor A2 (EphA2), P30-linked cytomegalovirus (CMV) matrix protein pp65 (65 kDa lower matrix phosphoprotein; UL83) and P30-linked survivin, with potential immunostimulating and antineoplastic activities. The vaccine may elicit a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing EphA2, CMV pp65 and survivin. (NCIT_C187131) Hiltonol is used as an adjuvant to stimulate or enhance the activation of your immune system. The vaccine and adjuvant may help treat HLA-A*0201 positive patients with a newly diagnosed, unmethylated, and untreated World Health Organization (WHO) grade IV malignant glioma. (NCIT_C187131)
|
| Host Response |
|
|
| References |
NCIT_C187131: P30-linked EphA2/CMV pp65/Survivin Peptide Vaccine P30-EPS [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C187131]
NCT05283109: ETAPA I: Peptide-based Tumor Associated Antigen Vaccine in GBM (ETAPA I) [https://clinicaltrials.gov/study/NCT05283109]
|
|
